On the basis of this data, we speculate that PSPH may play an important role in NSCLC progression and aggressiveness through the AKT/AMPK signaling pathway, and thus may be a novel therapeutic target for NSCLC. This evidence concerns the gene PSPH and non-small cell lung carcinoma.